Mito-FLAG regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} ==Overview== {{PAGENAME}} refers to a regimen consisting of mitoxantrone, fludarabine, cytarabine as bolus (B) or contin...") |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[mitoxantrone]], [[fludarabine]], [[cytarabine]] as bolus (B) or continuous infusion (CI) and [[G-CSF|granulocyte- colony stimulating factor]] (G-CSF) in patients with recurrent and refractory [[acute myeloid leukemia]] ([[AML]]).<ref name="pmid11574763">{{cite journal| author=Hänel M, Friedrichsen K, Hänel A, Herbst R, Morgner A, Neser S et al.| title=Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. | journal=Onkologie | year= 2001 | volume= 24 | issue= 4 | pages= 356-60 | pmid=11574763 | doi=55107 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11574763 }} </ref> | {{PAGENAME}} refers to a regimen consisting of [[mitoxantrone]], [[fludarabine]], [[cytarabine]] as bolus (B) or continuous infusion (CI) and [[G-CSF|granulocyte- colony stimulating factor]] (G-CSF) in patients with recurrent and refractory [[acute myeloid leukemia]] ([[AML]]).<ref name="pmid11574763">{{cite journal| author=Hänel M, Friedrichsen K, Hänel A, Herbst R, Morgner A, Neser S et al.| title=Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. | journal=Onkologie | year= 2001 | volume= 24 | issue= 4 | pages= 356-60 | pmid=11574763 | doi=55107 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11574763 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|Mito|Mitoxantrone}} | {{chemo|Mito|Mitoxantrone}} | ||
{{chemo|FL|Fludarabine}} | {{chemo|FL|Fludarabine}} | ||
{{chemo|A|Cytarabine (AraC)}} | {{chemo|A|Cytarabine (AraC)}} | ||
{{chemo|G|Granulocyte- colony stimulating factor}} | {{chemo|G|Granulocyte- colony stimulating factor}} | ||
==Indications== | ==Indications== | ||
*Recurrent and Refractory [[acute myeloid leukemia]] ([[AML]])<ref name="pmid11574763">{{cite journal| author=Hänel M, Friedrichsen K, Hänel A, Herbst R, Morgner A, Neser S et al.| title=Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. | journal=Onkologie | year= 2001 | volume= 24 | issue= 4 | pages= 356-60 | pmid=11574763 | doi=55107 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11574763 }} </ref> | *Recurrent and Refractory [[acute myeloid leukemia]] ([[AML]])<ref name="pmid11574763">{{cite journal| author=Hänel M, Friedrichsen K, Hänel A, Herbst R, Morgner A, Neser S et al.| title=Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. | journal=Onkologie | year= 2001 | volume= 24 | issue= 4 | pages= 356-60 | pmid=11574763 | doi=55107 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11574763 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
Latest revision as of 17:30, 27 March 2015
|
WikiDoc Resources for Mito-FLAG regimen |
|
Articles |
|---|
|
Most recent articles on Mito-FLAG regimen Most cited articles on Mito-FLAG regimen |
|
Media |
|
Powerpoint slides on Mito-FLAG regimen |
|
Evidence Based Medicine |
|
Cochrane Collaboration on Mito-FLAG regimen |
|
Clinical Trials |
|
Ongoing Trials on Mito-FLAG regimen at Clinical Trials.gov Trial results on Mito-FLAG regimen Clinical Trials on Mito-FLAG regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Mito-FLAG regimen NICE Guidance on Mito-FLAG regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Mito-FLAG regimen Discussion groups on Mito-FLAG regimen Patient Handouts on Mito-FLAG regimen Directions to Hospitals Treating Mito-FLAG regimen Risk calculators and risk factors for Mito-FLAG regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Mito-FLAG regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
Mito-FLAG regimen refers to a regimen consisting of mitoxantrone, fludarabine, cytarabine as bolus (B) or continuous infusion (CI) and granulocyte- colony stimulating factor (G-CSF) in patients with recurrent and refractory acute myeloid leukemia (AML).[1]
Regimen
MitoMitoxantrone
FLFludarabine
ACytarabine (AraC)
GGranulocyte- colony stimulating factor
Indications
- Recurrent and Refractory acute myeloid leukemia (AML)[1]